Bharat Parenterals Ltd
Bharat Parenterals Ltd Q1 FY27 Results & Presentation Highlights: Revenue ₹93.7 Cr, PAT ₹3.7 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Bharat Parenterals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Consolidated Revenue Q1 FY27: ₹93.7 Cr, down 19.2% YoY from ₹116.0 Cr in Q1 FY26. Consolidated Q1 FY27: - EBITDA: ₹8.5 Cr (9.1% margin) vs.
From Bharat Parenterals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Consolidated Revenue Q1 FY27: ₹93.7 Cr, down 19.2% YoY from ₹116.0 Cr in Q1 FY26.
- BPL Standalone Revenue Q1 FY27: ₹55.5 Cr, down 41.2% YoY from ₹94.4 Cr in Q1 FY26.
- Innoxel Revenue Q1 FY27: ₹21.4 Cr, up 165% YoY from ₹8.1 Cr in Q1 FY26.
- Varenyam Healthcare Revenue Q1 FY27: ₹25.1 Cr, up 52.2% YoY from ₹16.5 Cr in Q1 FY26.
- Volume: No explicit volume figures reported; Indian market volume growth cited at +0.6% (Page 9).
- Outlook:
- BPL Standalone growth guided at 10-15% YoY for FY27.
- Innoxel revenue growth 35-45% YoY targeted; commercial CMO supply starts Q2 FY27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Varenyam Bio Lifesciences (100% subsidiary)
- Project budget: ₹160 Cr
- CWIP: ₹33.22 Cr (20.8% of budget) as of Q1 FY27
- Civil work: 50% complete; equipment ordered 40%
- Planned lines: 2 oncology, 1 injectable with lyophilisation, 1 oral liquid
- Commissioning targeted: September 2027
- Line validation: March 2028
- First EU-GMP filing: Q1 FY29
- First commercial supply: Q4 FY29
- Facility location: Vadodara (under development)
- Innoxel Lifesciences
- Cumulative capex: ~₹250 Cr originally guided; ₹216.65 Cr spent by FY27 start
- FY26 capex: ₹22.83 Cr
- Lines validated: 4 cumulative
- First commercial CMO supply: Starts Q2 FY27
- BPL Standalone
- Capex FY26: ₹12.84 Cr; FY27 plan: ₹15 Cr
- QC lab expansion, robotic PFS filling, track & trace, roller compactor, ORABS and water system upgrades ongoing
- Overall
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Bharat Parenterals Limited standalone order book as of Q1 FY27: ₹171 Cr
- Domestic tenders: ₹119 Cr
- Exports: ₹33 Cr
- International tenders: ₹20 Cr
- This covers approximately 80–85% of the revenue needed over the remaining nine months to meet guided FY27 revenue.
- The order book relates to the ₹210 Cr institutional order's opening tranche.
- Domestic tender order book alone (single-state tenders) runs ₹880–965 Cr, indicating a larger market opportunity beyond current orders.
2 more points management made on order book & pipeline
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY27 investor presentation — and how it ranks against sect
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1
- NGL Fine Chem Ltd (Q1 FY27)
Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga
- Shree Ganesh Remedies Ltd (Q1 FY27)
Q1FY27 Revenue from Operations: ₹14.36 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY27 investor presentation — and how it rank
Frequently Asked Questions
What were Bharat Parenterals Ltd Q1 FY27 results?
Consolidated Revenue Q1 FY27: ₹93.7 Cr, down 19.2% YoY from ₹116.0 Cr in Q1 FY26. Consolidated Q1 FY27: - EBITDA: ₹8.5 Cr (9.1% margin) vs.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Bio Lifesciences (100% subsidiary) - Project budget: ₹160 Cr - CWIP: ₹33.22 Cr (20.8% of budget) as of Q1 FY27 - Civil work: 50% complete; equipment ordered 40% - Planned lines: 2 o
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.